Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two…
Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to…
Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma
Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA)…
Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma
Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA) for GLR2007 for the treatment of malignant glioma, an aggressive primary brain tumor. According to the Chinese biopharma company, GLR2007 is an inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which is being developed for the treatment of […]
Reyvow CENTURION trial results : Lilly migraine drug succeeds in phase 3 study
Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has…
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia
SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for…
Bruker acquires Missouri-based life science company Canopy Biosciences
US scientific instruments manufacturer Bruker Corporation has acquired Canopy Biosciences, a life science company engaged in providing high…
United Therapeutics appoints Dr Linda Maxwell to board of directors
United Therapeutics, a Maryland biotech company, has appointed head and neck surgeon Dr Linda Maxwell to its board…
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib)…
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]